ArticlePloS one2016
Antiviral Activity of Oroxylin A against Coxsackievirus B3 Alleviates Virus-Induced Acute Pancreatic Damage in Mice.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 33 citations in OpenAlex.
- Norwogonin aids in fighting MRSA-induced pneumonia by targeting agrAWorld journal of microbiology & biotechnology · 2024Article
- Antiviral and immunoregulatory effects of curcumin on coxsackievirus B3-infected hepatitis.Virus research · 2023Article
- Nutraceuticals and Their Contribution to Preventing Noncommunicable Diseases.Foods (Basel, Switzerland) · 2023Review
- Oroxylin A inhibited autoimmune hepatitis-induced liver injury and shifted Treg/Th17 balance to Treg differentiation.Experimental animals · 2023Article
- The Pharmacological Efficacy of Baicalin in Inflammatory Diseases.International journal of molecular sciences · 2023Review
- Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- Identification of phytochemicals in Qingfei Paidu decoction for the treatment of coronavirus disease 2019 by targeting the virus-host interactome.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Article
- Oroxylin A: A Promising Flavonoid for Prevention and Treatment of Chronic Diseases.Biomolecules · 2022Review
- Oroxylin A shows limited antiviral activity towards dengue virus.BMC research notes · 2022Article
- Therapeutics for fulminant hepatitis caused by enteroviruses in neonates.Frontiers in pharmacology · 2022Review
- Natural Phytochemicals, Luteolin and Isoginkgetin, Inhibit 3C Protease and Infection of FMDV, In Silico and In Vitro.Viruses · 2021Article
- Applications, phytochemistry, pharmacological effects, pharmacokinetics, toxicity ofChinese medicine · 2020Review
- Evidence of TCM Theory in Treating the Same Disease with Different Methods: Treatment of Pneumonia withEvidence-based complementary and alternative medicine : eCAM · 2020Article
- Principles and treatment strategies for the use of Chinese herbal medicine in patients at different stages of coronavirus infection.American journal of cancer research · 2020Review
- Manassantin B shows antiviral activity against coxsackievirus B3 infection by activation of the STING/TBK-1/IRF3 signalling pathway.Scientific reports · 2019Article
- Inhibitory Effects ofMolecules (Basel, Switzerland) · 2019Article
- Oroxylin A inhibits ethanol-induced hepatocyte senescence via YAP pathway.Cell proliferation · 2018Article
- Antiviral Activity of Itraconazole against Echovirus 30 InfectionOsong public health and research perspectives · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The flavonoids mosloflavone, oroxylin A, and norwogonin, which were purified from Scutellaria baicalensis Georgi, significantly protected Vero cells against Coxsackievirus B3 (CVB3)-induced cell death. To investigate the in vivo antiviral activity of oroxylin A, we intraperitoneally inoculated CVB3 into 4-week-old BALB/c mice. Body weights and blood glucose levels of the mice were decreased after CVB3 infection, and these changes were attenuated by the administration of oroxylin A. Importantly, treatment of mice with oroxylin A reduced viral titers in the pancreas and decreased the serum levels of the inflammatory cytokines including interleukin-6 (IL-6) and tumor necrosis factor (TNF)-α. Additionally, the administration of oroxylin A mitigated the histological pancreatic lesions and apoptotic cell death induced by CVB3 infection and increased the levels of phospho-eIF2α in infected pancreata. The results suggest that oroxylin A may represent a potent antiviral agent against CVB3 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.